Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors

Cancer Research

Volumn 59, Issue 9, 1999, Pages 2107-2114

  Sampath, Prakash ^b   Hanes, Justin ^b   DiMeco, Francesco ^b,c   Tyler, Betty M ^b   Brat, Daniel ^b   Pardoll, Drew M ^b   Brem, Henry ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; INTERLEUKIN 2; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0033135108     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Black, P. M. Brain tumors-part I. N. Engl. J. Med., 324: 1471-1476, 1991.
2. Black, P. M. Brain tumors-part II. N. Engl. J. Med., 324: 1555-1564, 1991.
3. Kornblith, P. L., and Walker, M. Chemotherapy for malignant gliomas. J Neurosurg., 63: 876-880, 1985.
4. Hochberg, F. H., and Pruitt, A. Assumptions in the radiotherapy of glioblastoma. Neurology, 30: 907-911, 1980.
5. Gansbacher, B , Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172: 1217-1224, 1990.
6. Fine, H. A. Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. Neurol. Clin., 13: 827-846, 1995.
7. Van Meir, E. G. Cytokines and tumors of the central nervous system. Glia, 15: 264-288, 1995.
8. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995
9. Thompson, R. C., Pardoll, D. M., Jaffee, E. M., Ewend, M. G., Thomas, M. C., Tyler, B. M., and Brem, H. Systemic and paracrine cytokine therapy using transduced tumor cells are synergistic in treating intracranial tumors. J. Immunother., 19: 405-413, 1997.
10. Fearon, E. R., Pardoll, D. M., and Itaya, T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
11. Ishida, Y., Nishi, M., and Taguchi, O. Expansion of natural killer cells but not T cells in human interleukin 2/interleukin 2 receptor (Tac) transgenic mice. J. Exp. Med., 170: 1103-1115, 1989.
12. Griffitt, W., Glick, R. P., Lichtor, T., and Cohen, E. P. Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system. Neurosurgery, 42: 335-340, 1998.
13. Lichtor, T., Glick, R. P., Kim, T. S., Hand, R., and Cohen, E. P. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J. Neurosurg., 83: 1038-1044, 1995.
14. Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., and Brem, H. Intratumoral chemotherapy. Neurosurgery, 37: 1128-1145, 1995.
15. Brem, H., and Langer, R. Controlled delivery to the brain. Sci. Am. Science & Medicine, 3: 52-61, 1996.
16. Tamargo, R. J., Myseros, J. S., Epstein, J. I., Yang, M. B., Chasin, M., and Brem, H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res., 53: 329-333, 1993.
17. Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., and Mohr, G. The Polymer-brain Tumor Treatment Group. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet, 345: 1008-1012, 1995.
18. Brem, H., Mahaley, M. S., Jr., Vick, N. A., Black, K. L., Schold, S. C., Jr., Burger, P. C., Friedman, A. H., Ciric, I. S., Eller, T. W., Cozzens, J. W., et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg., 74: 441-446, 1991.
19. Brem, H., Ewend, M. G., Piantadosi, S., Greenhoot, J., Burger, P. C., and Sisti, M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J. Neuro-oncol., 26: 111-123, 1995.
20. Valtonen, S., Timonen, U., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsgaard, G., and Kuurne, T. Placebo-controlled trial of Gliadel placement at the time of first surgery for malignant glioma. Neurosurgery, 40: 44-49, 1997.
21. Nigam, A., Yacavone, R. F., Zahurak, M. L., Johns, C. M. S., Pardoll, D. M., Piantadosi, S., Levitsky, H. I., and Nelson, W. G. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int. J. Oncol., 12: 161-170, 1998.
22. Tsung, K., Meko, J. B., Tsung, Y. L., Peplinski, G. R., and Norton, J. A. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol., 160: 1369-1377, 1998.
23. Pardoll, D. M. New strategies for enhancing the immunogenicity of tumors. Curr. Opin. Immunol., 5: 719-725, 1993.
24. Roszman, T., Elliott, L., and Brooks, W. Modulation of T-Cell Function by Gliomas. United Kingdom: Elsevier Science Publishers Ltd., 1991.
25. Dietrich, P., and de Tribolet, N. Immune response against malignant astrocy tic tumors and related therapy. In: C. Raffel and G. R. Harsh (eds.), The Molecular Basis of Neurosurgical Disease. Baltimore: Williams and Wilkins, 1996.
26. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H. I., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., and Mulligan, R. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating-factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
27. Sipos, E. P., Tyler, B., Piantadosi, S., Burger, P. C., and Brem, H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother. Pharmacol., 39: 383-389, 1997.
28. Olivi, A., Ewend, M. G., Utsuki, T., Tyler, B., Domb, A. J., Brat, D. J., and Brem, H. Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother. Pharmacol., 39: 90-96, 1996.
29. Ewend, G. E., Williams, J. A., Khosrow, T., Tyler, B., Babel, K. M., Andersen, R. C., Pinn, M. L., Brat, D. J., and Brem, H. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res., 56: 5217-5223, 1996.
30. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
31. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
32. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, D. R., Einhorn, J. H., and White, D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J. Am. Med. Assoc., 271: 907-913, 1994.
33. Staib, L., Harel, W., and Mitchell, M. S. Protection against experimental cerebral metastases of murine melanoma B16 by active immunization. Cancer Res., 53: 1113-1121, 1993.
34. Lillehei, K. O., Johnson, S. D., McCleary, E. L., Mitchell, D. H., Schiltz, P. M., and Kruse, C. A. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors. Online J. Curr. Clin. Trials, 1993.
35. Saris, S. C., Spiess, P., Lieberman, D. M., Lin, S., Walbridge, S., and Oldfield, E. H. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J. Neurosurg., 76: 513-519, 1992.
36. Merchant, R. E., McVicar, D. W., Merchant, L. H., and Young, H. F. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α: results of a phase I clinical trial. J. Neuro-oncol., 12: 75-83, 1992.
37. Barba, D., Saris, S. C., Holder, C., Rosenberg, S. A., and Oldfield, E. H. Intracranial LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg., 7: 175-182, 1989.
38. Hayes, R. L., Koslow, M., Hiesiger, E. M., Hymes, K. B., Hochster, H. S., Moore, E. J., Pierz, D. M., Chen, D. K., Budzilovich, G. N., and Ransohoff, J. Improved long term survival after intracavilary interleukin-2 and LAK cells for adults with recurrent malignant glioma. Cancer (Phila.), 76: 840-852, 1995.
39. Mickey, W. Migration of hematogenous cells through the blood brain barrier and the initiation of CNS inflammation. Brain Pathol., 1: 97-105, 1991.
40. Fontana, A., Hengartner, H., and de Tribolet, N. Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2-mediated effects. J. Immunol., 132: 1837-1844, 1984.
41. Akbasak, A., Oldfield, E. H., and Saris, S. C. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J. Neurosurg., 75: 922-929, 1991.
42. Streilein, W. J. Unraveling immune privilege. Science (Washington DC), 270: 1158-1159, 1995.
43. Kruse, C. A., Mitchell, D. H., Kleinschmidt-DeMasters, B. K., Bellgrau, D., Eule, J. M., Parra, J. R., Kong, Q., and Lillehei, K. O. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J. Neuro-oncol., 15: 97-112, 1993.
44. Mitsuoka, A., Baba, M., and Morikawa, S. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature (Lond.), 262: 77, 1976.
45. Carducci, M. A., Ayyagari, S. R., Sanda, M. G., and Simons, J. W. Gene therapy for human prostate cancer. Translational research in the hormone refractory Dunning prostate cancer model. Cancer (Phila.), 75: 2013-2020, 1995.
46. Sanda, M. G., Ayyagari, S. R., Jaffee, E. M., Epstein, J. I., Clift, S. L., Cohen, L. K., Dranoff, G., Pardoll, D. M., Mulligan, R. C., and Simons, J. W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol., 151: 622-628, 1994.
47. Fleming, I. D., Brady, L. W., Cooper, M. R., and Cooper, M. R. Basis for major current therapies for cancer, pp. 96-134. Atlanta: American Cancer Society, 1995.
48. Olivi, A., Gilbert, M., Duncan, K. L., Corden, B., Lenartz, D., and Brem, H. Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study. Cancer Chemother. Pharmacol., 31: 449-454, 1993.
49. Sampath, P., and Brem, H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control, 5: 31-38, 1998.